Core Insights - Akari Therapeutics, Plc is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, and has announced its abstract acceptance for presentation at the American Association for Cancer Research Annual Meeting 2026 [1][2] Group 1: Presentation Details - The poster presentation will focus on the rationale for developing a differentiated Trop2 ADC targeting solid tumors in the bladder, lung, and breast [2] - The presentation is scheduled for April 20, 2026, from 2:00 PM to 5:00 PM PT, under the session category of Experimental and Molecular Therapeutics [2] - The poster will be available for review on the company's website after the presentation [2] Group 2: Company Overview - Akari Therapeutics is developing next-generation ADCs, with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells using a proprietary linker to deliver the PH1 payload directly into tumors [4] - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, showing significant activity in preclinical studies and potential synergy with checkpoint inhibitors [4] - The company is also developing AKTX-102, targeting CEACAM5, which is expressed across multiple solid tumors, leveraging the same innovative PH1 payload [4]

Core Viewpoint - Akari Therapeutics is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to comply with Nasdaq's minimum bid price requirement, effective March 31, 2026 [1][2]. Group 1: ADS Ratio Change - The new ratio will be one ADS representing eighty thousand (80,000) ordinary shares, changing from the previous ratio of one ADS representing two thousand (2,000) ordinary shares [1][2]. - Each ADS holder will need to exchange every forty ADSs for one new ADS [2]. - Deutsche Bank will facilitate the exchange of current ADSs for new ADSs, and there will be no change to Akari's underlying ordinary shares [2]. Group 2: Fractional ADSs - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [3]. Group 3: Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, targeting RNA splicing [4]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, with potential synergy with checkpoint inhibitors [4]. - Akari is also developing AKTX-102, targeting CEACAM5, leveraging the proprietary PH1 payload for differentiated tumor cell killing and immune activation [4].

Varsetatug Masetecan: Phase 1 Dose Expansion Interim Data Update March 16, 2026 © 2026 CytomX Therapeutics, Inc. 1 Legal Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements rega ...

Core Insights - Akari Therapeutics has made significant strategic progress under the leadership of CEO Abizer Gaslightwala, focusing on the advancement of its proprietary PH1 ADC payload platform and the development of its lead program, AKTX-101 [2][3][4]. Strategic Developments - The company has sharpened its strategic focus and advanced the development of its PH1 ADC payload platform, positioning itself to transition into a clinical-stage biotechnology company [3]. - AKTX-101, the lead program, is a Trop2-targeted ADC utilizing the PH1 payload and a proprietary non-cleavable linker, with new preclinical data presented at major scientific conferences [4]. - A strategic manufacturing partnership with WuXi XDC has been established to support IND-enabling activities, aiming for IND or CTA submission for AKTX-101 by late 2026 or early 2027 [5]. Pipeline Expansion - Akari has introduced AKTX-102, targeting CEACAM5-expressing tumors, which aims to demonstrate the scalability of its "pipeline in a payload" strategy [6]. - The company has strengthened its intellectual property through multiple provisional patent filings related to the PH1 payload and its mechanisms [7]. Scientific Advancements - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing significant preclinical activity and potential synergy with checkpoint inhibitors [8][9].

Core Insights - ADC Therapeutics reported financial results for Q4 and full year 2025, highlighting a net product revenue of approximately $22.3 million for Q4 and $73.6 million for the full year, showing an increase from $16.4 million and $69.3 million in 2024 respectively [1][2] - The company anticipates topline data from the LOTIS-5 Phase 3 trial in Q2 2026, with full results expected by the end of 2026, and potential regulatory approval in mid-2027 [1][2] - Cash and cash equivalents stood at $261.3 million as of December 31, 2025, providing a cash runway expected to last at least into 2028 [1][2] Financial Performance - Q4 2025 net product revenue was $22.3 million, up from $16.4 million in Q4 2024, while full year revenue increased to $73.6 million from $69.3 million [1][2] - R&D expenses decreased to $18.2 million for Q4 2025 from $27.1 million in Q4 2024, and full year R&D expenses were $104.0 million compared to $109.6 million in 2024 [1][2] - The net loss for Q4 2025 was $6.4 million, or $0.04 per share, significantly reduced from a net loss of $30.7 million, or $0.29 per share in Q4 2024 [2][4] Operational Updates - The LOTIS-5 trial is expected to provide topline results in Q2 2026, with a supplemental Biologics License Application (sBLA) submission planned for mid-2027, assuming positive results [1][2] - The LOTIS-7 trial is ongoing, with data expected by the end of 2026, showing an 89.8% overall response rate and a 77.6% complete response rate in preliminary results [1][2] - Ongoing investigator-initiated trials are expected to yield data on ZYNLONTA's efficacy in treating additional B-cell malignancies between late 2026 and mid-2027 [1][2] Strategic Developments - An amendment to the HealthCare Royalty financing agreement was made in February 2026, reducing the change of control payment significantly, which enhances strategic flexibility for the company [2][4] - The company raised $150.8 million through PIPE financing in 2025, strengthening its cash position [2][4] - ADC Therapeutics continues to focus on innovation in antibody drug conjugates, with ZYNLONTA being a key product in its portfolio [1][2]

March 9, 2026 Legal Notices The information in this slide deck is current as of March 9, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and prospects for MacroGenics ("Company"), including statements about the Compan ...

Core Viewpoint - ADC Therapeutics will host a conference call on March 10, 2026, to report financial results for Q4 and the full year 2025, along with operational updates [1]. Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), focusing on transforming treatment for patients with its portfolio, including ZYNLONTA (loncastuximab tesirine-lpyl) [1]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [1]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to innovation in ADC development from clinical to commercialization [1]. Financial Results Announcement - The conference call will take place at 8:30 a.m. EDT, and participants are encouraged to join 10 minutes early [1]. - A live webcast will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [1].

Core Insights - Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology drug development as it advances its lead candidate AKTX-101 toward clinical trials [1][2][4] Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing, differentiating it from conventional ADCs that use tubulin inhibitors or DNA-damaging agents [7] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, indicating prolonged survival compared to traditional ADCs [7] - The company is also developing AKTX-102, which targets CEACAM5, a tumor antigen expressed across multiple solid tumors, leveraging the same PH1 payload for enhanced therapeutic effects [7] Dr. Prafulla Gokhale's Role - Dr. Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development, having previously led pharmacology teams at major pharmaceutical companies [4] - His expertise in experimental therapeutics and translational oncology is expected to strengthen Akari's clinical strategies for AKTX-101, ensuring a data-driven approach as the company prepares for first-in-human studies [2][6] Mechanism of Action - The PH1 payload is designed to modulate spliceosomes, disrupting RNA splicing within cancer cells, which has been shown to induce cancer cell death while engaging both innate and adaptive immune responses [5][7] - Preclinical models indicate that AKTX-101 may work synergistically with checkpoint inhibitors, enhancing its therapeutic potential [7]

Core Insights - ADC Therapeutics is participating in two investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1] Group 1: Upcoming Conferences - ADC Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:50 a.m. EST, with CEO Ameet Mallik as the speaker [1] - The company will also participate in the Jefferies Biotech on the Beach Summit on March 11, 2026, focusing on one-on-one meetings [1] Group 2: Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients [1] - The company's CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [1] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [1]

Core Insights - Akari Therapeutics is set to present at the 2026 Biocom Global Partnering & Investor Conference, highlighting its focus on oncology biotechnology and antibody drug conjugates (ADCs) with novel immuno-oncology payloads [1][2]. Company Overview - Akari Therapeutics specializes in developing next-generation ADCs, particularly focusing on a unique payload, PH1, which targets RNA splicing [3]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [3]. - PH1 is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing potential to induce cancer cell death while activating both innate and adaptive immune responses [3]. - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy when combined with checkpoint inhibitors [3]. - The company has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027 [3]. - Akari is also developing AKTX-102, targeting CEACAM5, a tumor antigen expressed in various solid tumors, leveraging the PH1 payload for enhanced tumor cell killing and immune activation [3].